Bli medlem
Bli medlem

Du är här


Immunovia AB: Immunovia starts collaboration with multinational life science company on new systemic lupus erythematosus (SLE) diagnostics test

Immunovia and a large multinational life science company have agreed
to run two studies aimed at evaluating Immunovia's IMMray™ SLE-d for
diagnosis of SLE

LUND, Sweden - Immunovia AB announced today that the company has
entered into an agreement with a large multinational life science
company to run joint studies aimed at expanding the applications area
of IMMray™, to autoimmune diseases. The market for SLE diagnosis is
large as it is estimated that 5 million people suffer from SLE
worldwide, with 100,000 new cases reported every year. As one of the
most difficult to diagnose and monitor autoimmune diseases, SLE is
also known as "the great imitator" because its symptoms are similar
to other diseases such as rheumatoid arthritis, vasculitis, Sjögrens
syndrome, thyroid and, blood disorders. Currently there is no single
serological and/or urinary test available to clinicians to diagnose

The two studies are due for completion during 2016. The first is a
randomized blind study on the IMMray™ SLE-d platform to further
validate Immunovia's current results. The second study will compare
an SLE cohort with patients with similar symptoms, but not autoimmune

"This agreement further strengthens and complements the previously
announced collaboration in autoimmunity with Lund University and we
find the market prospects very attractive," said Mats Grahn, CEO,
Immunovia. "We are looking forward to work closely with acknowledged
leaders in this challenging field to evaluate and further refine our
blood based antibody array for improved SLE diagnosis."

For more information, please contact:
Mats Grahn
Chief Executive Officer, CEO, Immunovia
Tel.: +46-70-5320230

For media relations:
Laura Chirica, PhD,
Chief Commercial Officer, CCO, Immunovia
Tel.: +46-70-9849035

Read more about Immunovia and IMMray™ technology:

About Immunovia
Immunovia AB was founded in 2007 by investigators from the Department
of Immunotechnology at Lund University and CREATE Health, the Center
for Translational Cancer Research in Lund, Sweden. Immunovia's
strategy is to decipher the wealth of information in blood and
translate it into clinically useful tools to diagnose complex
diseases such as cancer, earlier and more accurately than previously
possible. Immunovia's core technology platform, IMMray™, is based on
antibody biomarker microarray analysis. The company is now performing
clinical validation studies for the commercialization of IMMray™
PanCan-d that could be the first blood based test for early diagnosis
of pancreatic cancer. In the beginning of 2016, the company started
an autoimmunity diseases diagnosis prognosis and therapy monitoring
program, IMMray™ SLE-d being the first biomarker signature that is
now under evaluation and validation. (Source:

Immunovia's shares (IMMNOV) are listed on Nasdaq First North in
Stockholm and Wildeco is the company's Certified Adviser. For more
information, please visit

About Systemic Lupus Erythematosus (SLE) also known as "lupus"
It is estimated that 5 Million people suffer of SLE worldwide, with
100,000 new cases every year. Due to the challenge of diagnosing
correctly SLE patients, the incidence of new cases has been reported
to range between 1 and 10 per 100,000 person-years, while overall
prevalence varies between 20 and 70 per 100,000. A recent US study
estimated 1,500,000 US SLE patients (Lupus Foundation of America,
Center for disease control and prevention: SLE). In Sweden, there are
approximately 5000 SLE patients with 400 new patients diagnosed per


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.